Sanofi India Ltd

Sanofi India Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sanofi India Ltd

₹ 5,102 -0.10%
04 Mar - close price
sanofiindialtd.com BSE: 500674 NSE: SANOFI
About

Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]

Key Points

Parent Company[1]
Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence, Financial year is same as Calender Year.

Website BSE NSE
  • Market Cap ₹ 11,759 Cr.
  • Current Price ₹ 5,102
  • High / Low ₹ 7,600 / 4,146
  • Stock P/E 32.4
  • Book Value ₹ 374
  • Dividend Yield 3.27 %
  • ROCE 49.2 %
  • ROE 38.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 13.6 times its book value
  • Debtor days have increased from 29.3 to 41.7 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational

Part of BSE 250 SmallCap Index Nifty MidSmallcap 400 Nifty Total Market BSE 400 MidSmallCap Index Nifty Smallcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
515 491 469 511 464 524 515
393 377 370 374 348 404 397
Operating Profit 122 114 100 137 116 120 118
OPM % 24% 23% 21% 27% 25% 23% 23%
57 82 77 41 21 2 14
Interest 1 0 0 0 0 0 0
Depreciation 9 9 9 9 9 9 10
Profit before tax 169 186 167 169 127 113 122
Tax % 27% 18% 18% 19% 19% 27% 25%
123 152 138 137 103 82 91
EPS in Rs 53.43 66.04 59.87 59.39 44.87 35.74 39.70
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Dec 2024
2,851 2,013
2,044 1,522
Operating Profit 807 491
OPM % 28% 24%
79 78
Interest 2 2
Depreciation 40 37
Profit before tax 846 531
Tax % 29% 22%
603 413
EPS in Rs 262.13 179.70
Dividend Payout % 64% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -29%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -39%
Stock Price CAGR
10 Years: 9%
5 Years: 2%
3 Years: 5%
1 Year: -4%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 39%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Dec 2024
Equity Capital 23 23
Reserves 992 838
19 19
681 732
Total Liabilities 1,715 1,612
315 312
CWIP 16 18
Investments 0 0
1,384 1,281
Total Assets 1,715 1,612

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Dec 2024
230 462
38 -19
-878 -392
Net Cash Flow -610 50

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Dec 2024
Debtor Days 17 42
Inventory Days 202 186
Days Payable 89 151
Cash Conversion Cycle 130 77
Working Capital Days 25 21
ROCE % 49%

Shareholding Pattern

Numbers in percentages

Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40%
8.99% 8.71% 8.26% 6.99% 6.71% 6.72% 6.80% 6.31% 6.11% 5.81% 5.78% 5.64%
18.65% 18.59% 18.28% 19.22% 19.46% 19.65% 21.68% 22.51% 22.88% 22.60% 22.62% 22.94%
11.96% 12.30% 13.08% 13.41% 13.43% 13.22% 11.10% 10.78% 10.61% 11.21% 11.20% 11.04%
No. of Shareholders 59,27664,54273,73474,59376,69471,51368,59862,87061,84967,66266,21166,401

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls